Sentence examples for inefficacy to from inspiring English sources

A meta‐analysis of results reported in these studies indicate that the inefficacy to improve the mortality rate of the peptide‐guided compared to the control group found in some studies, may depend on to the inability of current therapeutic strategies to modify prognosis, especially in the elderly subset of patients, who are characterized by more advanced disease and comorbidities.

15 These observations strongly suggested that IGF1R is a unique RTK gene that could be used as a predictive biomarker for inefficacy to PI3K inhibitors.

However, the inefficacy to spontaneously clear airways from an excessive burden of respiratory secretions is likely to cause NPPV failure [ 3, 4].

In contrast to the inefficacy to KKU-M214 cells, NAC almost fully protected Chang cells from the cytotoxic effect of PEITC at any time points examined after incubation.

The therapeutic arsenal now available to manage T2DM has proved inefficacy to prevent the rise in incidence of cardiovascular events, the leading cause of morbidity and early mortality of diabetic patients.

In contrast, patients with secondary inefficacy to TNF inhibitors may have lost response because of the development of drug antibodies; these patients would therefore be expected to exhibit a response to an antigenically distinct treatment, whether within or distinct from the previous class.

Consequently, ∼10% of patients had discontinued therapy due to inefficacy prior to the 6-month follow-up and some will have commenced alternative treatment to which they may have responded.

Moreover, significantly more patients from the sham acupuncture group dropped out prematurely due to inefficacy compared to the 2 acupuncture groups.

In his worsted suit and modified brush cut, hands clasped skittishly behind his back, the 42-year-old Layden seemed the very picture of front-office inefficacy, unable to reach out to a player only an arm's length away.

All patients were treated with anti-TNF drugs and mainly due to inefficacy were switched to a second anti-TNF drug.

During 20 198 person-years (mean/median 2.2/1.7 years) of follow-up, 3782 patients discontinued their first biological (19/100 person-years; 51% due to inefficacy, 36% due to adverse events).